We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma.
- Authors
Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G.
- Abstract
B Background: b The Phase II L-MIND study led to accelerated US approval and EU conditional authorization of the CD19-targeted immunotherapy, tafasitamab, + lenalidomide (LEN) followed by tafasitamab monotherapy for patients (pts) with R/R DLBCL ineligible for autologous stem cell transplant (ASCT). B Conclusion: b In this 5-yr subgroup analysis, a long-term clinical benefit with tafasitamab + LEN followed by tafasitamab monotherapy was observed in all subgroups of clinical interest, including pts with poor prognosis risk factors.
- Subjects
DIFFUSE large B-cell lymphomas; LENALIDOMIDE; SUBGROUP analysis (Experimental design)
- Publication
Hematological Oncology, 2023, Vol 41, p439
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_324